What happened

The FDA granted accelerated approval on August 13 to Zenbexus (iberdomide), a cereblon-modulating protein degrader, for use in combination with daratumumab, hyaluronidase-fihj and dexamethasone in patients with relapsed or refractory multiple myeloma -- a cancer of plasma cells in the bone marrow. The approval covers patients who have received at least one prior line of therapy.

What we know

The approval was based on data from the phase 3 EXCALIBER-RRMM trial, which compared the new combination therapy against a standard regimen of daratumumab, bortezomib and dexamethasone in patients whose multiple myeloma had relapsed or stopped responding to earlier treatment. The FDA had granted the drug Priority Review status, reflecting the agency's assessment that it could offer a significant improvement over available therapies for this patient population. The trial measured progression-free survival -- the length of time patients lived without their disease worsening -- as its primary endpoint, a standard measure used in cancer drug trials to gauge whether a new treatment meaningfully delays disease progression compared with existing standards of care.

Understanding the disease

Multiple myeloma is the second most common blood cancer in the United States, typically diagnosed in older adults, with a median age at diagnosis in the late 60s. It develops when plasma cells -- a type of white blood cell that normally produces antibodies -- grow out of control in the bone marrow, crowding out healthy blood cells and often producing abnormal proteins that can damage the kidneys and weaken bones. While treatment has improved substantially over the past two decades, multiple myeloma is still generally considered incurable with current therapies; most patients cycle through several different treatment regimens over the course of their disease as each one eventually stops working.

Why it matters

Multiple myeloma remains difficult to cure, and most patients eventually relapse even after responding to initial treatment, making new options for relapsed or refractory disease clinically significant. Cereblon-modulating drugs like iberdomide work by targeting specific proteins that cancer cells depend on to survive, a mechanism that has become an increasingly important tool in myeloma treatment over the past decade. Iberdomide is part of the same drug class as lenalidomide and pomalidomide, two cereblon-modulating drugs already widely used in myeloma treatment, but it was engineered to bind more tightly to its target protein, which researchers have hypothesized could translate into stronger anti-cancer activity, particularly in patients whose disease has become resistant to earlier drugs in the same class.

Who is affected

An estimated 35,000 to 36,000 new multiple myeloma cases are diagnosed in the United States each year, according to figures the American Cancer Society has published in recent years. The newly approved combination is specifically intended for patients who have already tried at least one prior treatment regimen and whose disease has either stopped responding or has come back -- a population that often has fewer remaining treatment options and a more guarded prognosis than patients who are newly diagnosed.

Background

The approval is part of a broader wave of FDA drug decisions in early-to-mid August, including approvals for a narcolepsy treatment and an engineered viral immunotherapy for advanced melanoma. Accelerated approval allows the FDA to authorize drugs for serious conditions based on evidence the agency considers reasonably likely to predict clinical benefit, with the requirement that the manufacturer conduct further studies to confirm that benefit. This pathway has been used for numerous cancer therapies over the past decade, allowing patients earlier access to promising treatments while additional data on long-term outcomes, such as overall survival, continues to be collected.

What remains unresolved

Because the approval relies on progression-free survival data rather than mature overall survival results, it will take additional follow-up time to confirm whether the new combination extends how long patients live, not just how long their disease stays under control. Pricing for the new therapy had not been publicly disclosed at the time of approval, and insurance coverage decisions -- which can significantly affect how quickly a newly approved drug reaches patients in practice -- typically take additional time to finalize after FDA approval.

What happens next

The drug's manufacturer is expected to continue confirmatory trials to verify the treatment's clinical benefit, a standard condition of accelerated approval. Oncologists treating multiple myeloma patients will now be able to consider the new combination as an option for patients whose disease has relapsed after earlier lines of therapy, and the National Comprehensive Cancer Network and other clinical guideline bodies are expected to evaluate whether to incorporate the new regimen into their treatment recommendations in the coming months.

Sources

This article is based on the FDA's official press announcement of the approval.